Verified Specialists · Case-Anchored · Global Reach
Physician surveys built for
low-volume experience
Surveying physicians in rare disease is fundamentally different from surveying physicians in high-prevalence therapeutic areas. The pool of treating specialists is small, key opinion leaders are identifiable by name within their subspecialty, and the clinical experience base any single physician can draw on is often limited to a handful of patients.
MedPanel’s physician and KOL survey practice is built around these constraints — combining a verified specialist panel, global reach into niche subspecialty networks, and survey design that respects the realistic limits of what a rare disease physician can report with confidence.
Treating physicians per country, per condition
Patient volume · Recency · Pathway role
Case-anchored, 20–30 minutes
N. America · Europe · Asia-Pacific · LATAM
Why Physician and KOL Research Requires a Different Recruitment Model
In rare disease, the entire universe of physicians treating a condition in a country may number in the dozens — which changes the recruitment math and raises the stakes on every respondent.
- The recruitment math is entirely different. In a common disease category, a market research panel can recruit hundreds of treating physicians without difficulty. In rare disease, the entire universe of physicians actively treating a given condition in a country may number in the dozens. This changes the recruitment math entirely — and it raises the stakes on every single respondent’s data quality, because there is no large sample to average out noise.
- Verification guards against unqualified self-classification. MedPanel maintains a verified network of rare disease treating physicians and key opinion leaders built through years of subspecialty recruitment, conference-based outreach, and partnership with patient advocacy and clinical research networks. The risk here is not fraudulent identity but unqualified self-classification — a general practitioner or adjacent specialist who has seen one or two cases self-identifying as having meaningful experience. MedPanel screens for actual patient volume, treatment recency, and role in the diagnostic or treatment pathway, not just specialty title.
- KOL identification follows a distinct methodology. Key opinion leaders are typically identified through publication history, conference presentation records, clinical trial investigator status, and guideline committee participation. MedPanel’s research team cross-references these markers before extending recruitment invitations, ensuring that KOL-labeled responses in your dataset reflect genuine field leadership rather than self-reported seniority.
Survey Design for Low-Volume Clinical Experience
Most respondents have treated a small number of patients with the target condition — sometimes single digits over an entire career — so survey design must extract maximum signal without asking for estimates physicians cannot reliably provide.
The central design challenge in rare disease physician surveys is that most respondents have treated a small number of patients with the target condition. Standard physician survey formats that ask for aggregate impressions (“In your experience, what percentage of your patients…”) produce unreliable estimates when the denominator is five or ten patients.
Case-anchored questioning
Rather than asking physicians to generalize, surveys are structured around specific recent patients the physician has treated — diagnostic journey, treatment selection rationale, monitoring approach, and outcome for that individual case. This produces granular, attributable data rather than impressionistic estimates, and it is more cognitively comfortable for physicians to answer, since it draws on episodic memory rather than statistical estimation they are not equipped to provide.
Treatment decision mapping
Rare disease treatment pathways frequently involve diagnostic odysseys spanning multiple specialists before a definitive diagnosis is reached. Physician surveys that capture only the treating specialist’s perspective miss the referral pattern and diagnostic delay dynamics that matter enormously to commercial and access strategy. MedPanel survey design accounts for the physician’s specific role in the pathway — diagnosing, referring, or treating — and tailors question sets accordingly rather than applying one instrument across all physician types.
Length and format
MedPanel typically recommends 20–30 minute instruments for physician and KOL surveys, longer than standard patient surveys but shorter than full in-depth interview engagements, structured to extract maximum signal from a necessarily small and high-value respondent pool.
Global Reach Across Rare Disease Subspecialties
Rare disease expertise is unevenly distributed, often concentrated in a few specialist centers per country — so single-market programs frequently miss strategic relevance for global launch planning.
Rare disease treatment expertise is often concentrated in a small number of specialist centers per country or region. A physician survey program limited to a single market will frequently fail to reach statistical or strategic relevance for global launch planning.
MedPanel’s physician network spans North America, Europe, and expanding coverage across Asia-Pacific and Latin America, allowing sponsors to field comparative surveys that capture how treatment approach, diagnostic pathway, and access barriers vary by healthcare system. This is particularly valuable for orphan drug programs pursuing simultaneous or staggered regulatory submissions across multiple regions, where understanding physician readiness and current standard-of-care variation directly informs launch sequencing and medical affairs planning.
For programs requiring institutional review, MedPanel provides IRB-ready documentation covering physician consent language, data handling protocols, and disclosure requirements specific to healthcare provider research — distinct from patient-facing IRB submissions and requiring separate regulatory attention.
From Survey Data to Strategic Input
Physician and KOL survey data is most valuable when it feeds directly into your broader evidence and access strategy rather than standing alone.
Physician and KOL survey data in rare disease rarely stands alone. It is most valuable when triangulated with qualitative input — advisory board discussions, in-depth interviews with top-tier KOLs, and patient-side research that contextualizes the clinical perspective against lived disease experience. MedPanel’s survey practice is designed to integrate with these complementary methodologies rather than operate as an isolated data collection exercise, ensuring that the quantitative signal you collect from physicians feeds directly into the broader evidence and access strategy your program requires.
Scope your survey
Reach the Physicians Who Actually Treat Your Target Condition
Rare disease physician and KOL research succeeds or fails on recruitment quality. MedPanel’s verified specialist network, global reach, and case-anchored survey design ensure that every response in your dataset comes from a physician with genuine, attributable experience treating the condition you are studying.
Verified specialist network screened for real patient volume
Case-anchored design for attributable, granular data
Global reach for comparative, multi-market fielding
IRB-ready documentation for healthcare provider research
Contact MedPanel to scope your physician and KOL survey program. We will confirm specialist availability in your target markets and outline a design approach suited to your clinical and commercial objectives.